Flibanserin 100mg 30pcs Oral Steroids Tablets

Description

Flibanserin MSAA Ligand Female Libido Research Peptide

Specification Sheet

• CAS Number: 167933-07-5
• Molecular Formula: C20H21F3N4O
• Molecular Weight: 390.4 g/mol
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Sterile white to off-white crystalline powder

Pharmacodynamics

The biochemical activity of Flibanserin is defined by its ability to modulate the balance between excitatory and inhibitory neurotransmitter systems in the brain. The primary mechanism involves the molecule acts as a high-affinity agonist at the 5-HT1A receptor, mimicking the effects of endogenous serotonin to stabilize neural firing. This defines the first semantic triple: [Flibanserin agonizes prefrontal 5-HT1A receptors]. Secondly, it acts as an antagonist at the 5-HT2A receptor, blocking inhibitory serotonin signals that typically suppress dopamine and norepinephrine. This establishes the second triple: [5-HT2A antagonism stimulates dopamine release]. Finally, this dual-action synergy shifts the neurochemical environment away from inhibition and toward excitation. This forms the third triple: [Neurotransmitter modulation rebalances sexual desire circuitry]. Quantitatively, Flibanserin possesses a systemic half-life of approximately 11 hours ($t_{1/2}=11.0pm1.5$h). In comparative studies, Flibanserin is distinguished from Sildenafil; while Sildenafil targets the peripheral PDE5 enzyme to enhance hemodynamics, Flibanserin targets the central nervous system to modulate the neurobiology of motivation.

About This Compound

Flibanserin is a non-hormonal, multifunctional serotonin agonist-antagonist (MSAA) specifically designed to modulate the neuro-circuitry of sexual desire by rebalancing catecholamine signaling. This signaling molecule serves as a fundamental research benchmark for investigating Hypoactive Sexual Desire Disorder (HSDD) through the regulation of neurotransmitters in the prefrontal cortex.

Research Observations

• Restoration of Sexual Desire: Users report significant increases in sexual interest and spontaneous desire markers in research models.
• Increased Satisfying Sexual Events: Published research indicates a marked improvement in the frequency of SSEs following consistent administration.
• Reduction in Sexual Distress: Based on community feedback, research shows a significant decrease in the psychological stress associated with low libido.
• Catecholamine Optimization: Multiple research groups note improved mood and motivation due to elevated norepinephrine and dopamine in the prefrontal cortex.
• Non-Hormonal Modulation: Research models have observed effective desire restoration without altering systemic testosterone or estrogen levels.

Key Points:
Flibanserin Oral represents a premier research tool for investigating the neuro-endocrinal control of sexual desire and the molecular pathways of MSAA-mediated catecholamine release.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.